Patents by Inventor Stefan H. E. Kaufmann

Stefan H. E. Kaufmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for the detection of a latent tuberculosis infection
    Patent number: 11767566
    Abstract: The present invention relates to a method for the in vitro detection of a latent tuberculosis infection (LTBI) in a subject, wherein said method comprises determining at least one nucleotide sequence and/or at least one polypeptide of Mycobacterium tuberculosis (Mtb) in a blood cell population of said subject, and wherein the presence of said at least one nucleotide sequence and/or said at least one polypeptide is indicative for said latent tuberculosis infection. In particular, the blood cell population is enriched for hematopoietic stem cells. The invention also relates to a pharmaceutical composition for use in the treatment of the LTBI in the subject, wherein it is determined if the nucleotide sequence and/or the polypeptide of Mtb is/are present in the blood cell population. Further, the invention relates to kits for carrying out the methods of the invention. The invention also relates to the use of the kits.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: September 26, 2023
    Assignees: Max-Planck-Gesellschaft, Medizinische Universität Wien
    Inventors: Julia Tornack, Stephen Reece, Fritz Melchers, Stefan H. E. Kaufmann, Wolfgang Bauer, Georg Stingl
  • Method for predicting progression to active tuberculosis disease
    Patent number: 11613782
    Abstract: The invention provides a gene signature for use in determining a likelihood of a latent tuberculosis (TB) infection in a subject transitioning to active TB disease. The gene signature comprises at least SEPT4 and BLK, and optionally also GAS6 and/or CD1C. Expression levels of these genes are detected in a sample from the subject, and the ratios of expression of at least two of the above genes are calculated (e.g. SEPT4:BLK, SEPT4:CD1C, GAS6:BLK and/or GAS6:CD1C). A score is assigned to each ratio, the score being indicative of the likelihood of the latent TB infection transitioning into active TB disease, based on the ratio for the respective gene pair. The subject can be identified as having a latent TB infection that is likely to transition into active TB disease or that is not likely to transition into active TB disease based on the score or on the average of the scores.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: March 28, 2023
    Assignees: UNIVERSITY OF CAPE TOWN, STELLENBOSCH UNIVERSITY, SEATTLE CHILDREN'S HOSPITAL, MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V, UNITED KINGDOM RESEARCH AND INNOVATION
    Inventors: Sara Suliman, Ethan Greene Thompson, Jayne Suzanne Sutherland, Stefan H. E. Kaufmann, Thomas Jens Scriba, Daniel Edward Zak, Gerhard Walzl
  • METHOD FOR PREDICTING PROGRESSION TO ACTIVE TUBERCULOSIS DISEASE
    Publication number: 20210363580
    Abstract: The invention provides a gene signature for use in determining a likelihood of a latent tuberculosis (TB) infection in a subject transitioning to active TB disease. The gene signature comprises at least SEPT4 and BLK, and optionally also GAS6 and/or CD1C. Expression levels of these genes are detected in a sample from the subject, and the ratios of expression of at least two of the above genes are calculated (e.g. SEPT4:BLK, SEPT4:CD1C, GAS6:BLK and/or GAS6:CD1C). A score is assigned to each ratio, the score being indicative of the likelihood of the latent TB infection transitioning into active TB disease, based on the ratio for the respective gene pair. The subject can be identified as having a latent TB infection that is likely to transition into active TB disease or that is not likely to transition into active TB disease based on the score or on the average of the scores.
    Type: Application
    Filed: March 13, 2019
    Publication date: November 25, 2021
    Inventors: Sara Suliman, Ethan Greene Thompson, Jayne Suzanne Sutherland, Stefan H.E. Kaufmann, Thomas Jens Scriba, Daniel Edward Zak, Gerhard Walzl
  • METHODS FOR THE DETECTION OF A LATENT TUBERCULOSIS INFECTION
    Publication number: 20190226011
    Abstract: The present invention relates to a method for the in vitro detection of a latent tuberculosis infection (LTBI) in a subject, wherein said method comprises determining at least one nucleotide sequence and/or at least one polypeptide of Mycobacterium tuberculosis (Mtb) in a blood cell population of said subject, and wherein the presence of said at least one nucleotide sequence and/or said at least one polypeptide is indicative for said latent tuberculosis infection. In particular, the blood cell population is enriched for hematopoietic stem cells. The invention also relates to a pharmaceutical composition for use in the treatment of the LTBI in the subject, wherein it is determined if the nucleotide sequence and/or the polypeptide of Mtb is/are present in the blood cell population. Further, the invention relates to kits for carrying out the methods of the invention. The invention also relates to the use of the kits.
    Type: Application
    Filed: June 6, 2017
    Publication date: July 25, 2019
    Applicants: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Medizinische Universität Wien
    Inventors: Julia Tornack, Steephen REECE, Fritz MELCHERS, Stefan H.E. KAUFMANN, Wolfgang BAUER, Georg STINGL
  • Recombinant as a vaccine
    Patent number: 9879268
    Abstract: The invention relates to a recombinant Mycobacterium cell for use as a vaccine.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: January 30, 2018
    Assignees: Vakzine Projekt Management GmbH, Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Christine Desel, Stefan H. E. Kaufmann, Silke Bandermann, Leander Grode
  • RECOMBINANT MYCOBACTERIUM AS A VACCINE
    Publication number: 20160184419
    Abstract: The invention relates to a recombinant Mycobacterium cell for use as a vaccine.
    Type: Application
    Filed: March 4, 2016
    Publication date: June 30, 2016
    Applicants: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Vakzine Projekt Management GmbH
    Inventors: Christine DESEL, Stefan H.E. Kaufmann, Silke Bandermann, Leander Grode
  • Recombinant mycobacterium as a vaccine
    Patent number: 9328350
    Abstract: The invention relates to a recombinant Mycobacterium cell for use as a vaccine.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: May 3, 2016
    Assignees: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Vakzine Projekt Management GmbH
    Inventors: Christiane Desel, Stefan H. E. Kaufmann, Silke Bandermann, Leander Grode
  • Determination of the efficacy of an anti-mycobacterial vaccination
    Patent number: 8906389
    Abstract: The invention relates to methods and reagents for determining efficacy of vaccine, particularly of a tuberculosis vaccine.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: December 9, 2014
    Assignees: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Vakzine Projekt Management GmbH
    Inventors: Christiane Desel, Stefan H. E. Kaufmann, Silke Bandermann, Leander Grode
  • RECOMBINANT MYCOBCTERIUM AS A VACCINE
    Publication number: 20130337011
    Abstract: The invention relates to a recombinant Mycobacterium cell for use as a vaccine.
    Type: Application
    Filed: December 21, 2011
    Publication date: December 19, 2013
    Applicants: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Vakzine Projekt Management GmbH
    Inventors: Christiane Desel, Stefan H.E. Kaufmann, Silke Bandermann, Leander Grode
  • DETERMINATION OF THE EFFICACY OF AN ANTI-MYCOBACTERIAL VACCINATION
    Publication number: 20130280739
    Abstract: The invention relates to methods and reagents for determining efficacy of vaccine, particularly of a tuberculosis vaccine.
    Type: Application
    Filed: December 21, 2011
    Publication date: October 24, 2013
    Applicants: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Vakzine Projekt Management GmbH
    Inventors: Christiane Desel, Stefan H.E. Kaufmann, Silke Bandermann, Leander Grode
  • Tuberculosis vaccine with improved efficacy
    Patent number: 8545854
    Abstract: The present invention relates to novel recombinant vaccines providing protective immunity against tuberculosis. Further, the present invention refers to novel recombinant nucleic acid molecules, vectors containing said nucleic acid molecules, cells transformed with said nucleic acid molecules and polypeptides encoded by said nucleic acid molecules.
    Type: Grant
    Filed: June 22, 2011
    Date of Patent: October 1, 2013
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenshaften, e.V.
    Inventors: Leander Grode, Stefan H. E. Kaufmann, Baerbel Raupach, Juergen Hess
  • TUBERCULOSIS VACCINE WITH IMPROVED EFFICACY
    Publication number: 20120027794
    Abstract: The present invention relates to novel recombinant vaccines providing protective immunity against tuberculosis. Further, the present invention refers to novel recombinant nucleic acid molecules, vectors containing said nucleic acid molecules, cells transformed with said nucleic acid molecules and polypeptides encoded by said nucleic acid molecules.
    Type: Application
    Filed: June 22, 2011
    Publication date: February 2, 2012
    Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Leander GRODE, Stefan H.E. KAUFMANN, Barbel RAUPACH, Jürgen HESS
  • Tuberculosis vaccine with improved efficacy
    Patent number: 7988980
    Abstract: The present invention relates to novel recombinant vaccines providing protective immunity against tuberculosis. Further, the present invention refers to novel recombinant nucleic acid molecules, vectors containing said nucleic acid molecules, cells transformed with said nucleic acid molecules and polypeptides encoded by said nucleic acid molecules.
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: August 2, 2011
    Assignee: Max-Planck-Gesellschaft zur Foerderung Der Wissenshaften e. V.
    Inventors: Leander Grode, Stefan H. E. Kaufmann, Bärbel Raupach, Jürgen Hess
  • Identification of specific differentially expressed antigens
    Patent number: 7772386
    Abstract: The present invention relates to compositions useful in immunization against pathogenic organisms of the genus Mycobacterium and for diagnostic purposes. In particular, the present invention relates to a composition comprising at least one protein which is differentially expressed in a virulent strain as compared to an avirulent strain of Mycobacteria. Furthermore, the invention relates to compositions comprising fusion proteins, antigenic fragments, nucleic acid molecules encoding the aforementioned proteinaceous compounds and/or antibodies thereto. Additionally, the invention relates to pharmaceutical and diagnostic compositions comprising or employing compounds of the invention. In addition, the present invention relates to the use of the compounds of the invention for the treatment of Mycobacterium induced diseases and/or for the preparation of a vaccine for vaccination against Mycobacterium induced diseases.
    Type: Grant
    Filed: January 28, 2000
    Date of Patent: August 10, 2010
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.
    Inventors: Peter Jungblut, Stefan H. E. Kaufmann, Ulrich Schaible, Hans Mollenkopf, Bärbel Raupach, Ursula Zimny-Arndt, Stephanie Lamer, Jens Mattow
  • Structures of Active Guide Rna Molecules and Method of Selection
    Publication number: 20080280848
    Abstract: The present invention relates to methods and compositions for modulating RNA silencing efficiency by providing selective RISC (RNA-induced silencing complex) formation. The present invention also relates to methods for identifying nucleic acids and/or determining their structures.
    Type: Application
    Filed: October 27, 2006
    Publication date: November 13, 2008
    Inventors: Volker Patzel, Stefan H. E. Kaufmann
  • Tuberculosis vaccine
    Patent number: 6776993
    Abstract: The present invention relates to novel recombinant vaccines providing protective immunity against tuberculosis. Further, the present invention refers to novel recombinant nucleic acid molecules, vectors containing said nucleic acid molecules, cells transformed with said nucleic acid molecules and polypeptides encoded by said nucleic acid molecules.
    Type: Grant
    Filed: September 10, 2001
    Date of Patent: August 17, 2004
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Stefan H. E. Kaufmann, Jürgen Hess
  • Tuberculosis vaccine
    Patent number: 6673353
    Abstract: The present invention relates to novel recombinant vaccines providing protective immunity against tuberculosis. Further, the present invention refers to novel recombinant nucleic acid molecules, vectors containing said nucleic acid molecules, cells transformed with said nucleic acid molecules and polypeptides encoded by said nucleic acid molecules.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: January 6, 2004
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
    Inventors: Stefan H. E. Kaufmann, Jürgen Hess
  • Tuberculosis vaccine
    Publication number: 20020177569
    Abstract: The present invention relates to novel recombinant vaccines providing protective immunity against tuberculosis. Further, the present invention refers to novel recombinant nucleic acid molecules, vectors containing said nucleic acid molecules, cells transformed with said nucleic acid molecules and polypeptides encoded by said nucleic acid molecules.
    Type: Application
    Filed: September 10, 2001
    Publication date: November 28, 2002
    Inventors: Stefan H.E. Kaufmann, Jurgen Hess